Application of co-expressed genes to articular cartilage: New hope for the treatment of osteoarthritis (Review)

RONG WAN1*, JIONG HU2*, QI ZHOU1, JUN WANG1 PEIYI LIU1 and YIYONG WEI1

1Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases with Integrated Chinese-Western Medicine, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025; 2Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang Traditional Chinese Medicine University, Hangzhou, Zhejiang 310005, P.R. China

Received August 2, 2011; Accepted October 21, 2011

DOI: 10.3892/mmr.2012.859

Abstract. Osteoarthritis (OA), with a high prevalence and economic impact, is a progressive diarthrodial joint disease that substantially reduces quality of life and is mainly characterized by degradation of the extracellular matrix (ECM) and the loss of a chondrogenic phenotype in articular cartilage. Strategic targeting of therapeutic genes to OA cartilage may offer potent alternatives for restoring the structure of the damaged cartilage. α2-macroglobulin (α2M), a member of the α2M family of proteins, prevents the degradation of the ECM by inhibiting the activity of a disintegrin-metalloproteinases with thrombospondin motifs (ADAMTSs) and matrix metalloproteinases (MMPs). Sox9, a key chondrogenic transcription factor, plays a crucial role in the development and maintenance of the chondrogenic phenotype. Therefore, modulation of the OA cartilage by genetically modifying the levels of α2M and Sox9 expression may be advantageous in ameliorating the course of OA. To acquire long-lasting expression of the α2M and Sox9 genes, gene transfer systems are required. The chitosan vector system is expected to be useful for direct gene therapy for joint disease. Thus, we conclude that co-expression of the α2M and Sox9 genes, combined with chitosan-mediated gene delivery, will offer potential as a novel means by which to treat OA via intra-articular injection.

Contents

1. Osteoarthritic characteristics
2. Damage of cartilage matrix and α2-macroglobulin
3. Loss of chondrogenic phenotype and Sox9
4. Gene therapy of osteoarthritis
5. Future directions

1. Osteoarthritic characteristics

Osteoarthritis (OA) is a degenerative joint disease that significantly impacts quality of life. Numerous factors varying from mechanical disruption to gene mutations in structural proteins have been proposed as contributors to the development of OA. The progression of the disease is slow and a frequent end point is destruction of the articular cartilage, which leads to limitation of joint movement, joint deformity, inflammation and severe pain (1). The pathological characteristics of OA are predominantly involved in the degradation of the extracellular matrix (ECM) and loss of a chondrogenic phenotype in cartilage.

2. Damage of cartilage matrix and α2-macroglobulin

Among the mechanisms responsible for OA cartilage matrix damage, disintegrin-metalloproteinases with thrombospondin motifs (ADAMTSs) and the matrix metalloproteinases (MMPs) have been indentified as being of key importance (Fig. 1). ADAMTSs are the main proteinases responsible for the cleavage of aggrecan and cartilage oligomeric matrix protein (COMP, a prominent noncollagenous component of cartilage) in the early event of OA. Later, MMPs participate in the process and continue with the degradation of collagen (2). A number of the ADAMTS protein family, including ADAMTS-1, -4, -5, -7 and -12, play a crucial role in the process of OA. The study demonstrated that ADAMTS-4 and ADAMTS-5 had intensive aggrecan-degradation activity compared to other aggrecanases (ADAMTS-1) in vitro and were currently recognized as the most active aggrecanases in vivo (3,4). In addition to aggrecan, ADAMTS-4 was also shown to cleave COMP (5). A recent study demonstrated that ADAMTS-7 and -12 were also able to digest COMP in vitro, and that their levels were significantly upregulated in OA (6). The MMPs consist of a number of subsets of enzymes...
including collagenases, gelatinases, stromelysins, matrilysins and the membrane-type MMPs. The most significant members of the MMP family with respect to OA are the collagenases (MMP-1, -8 and -13). Of the collagenases, MMP-13 prefers to cleave type II collagen while MMP-1 and MMP-8 prefer to cleave types III and I. In addition to collagen, MMP-13 also degrades the proteoglycan molecule, aggrecan, giving it a dual role in matrix destruction (7,8).

Therapies aimed at inhibiting the activity of ADAMTSs and MMPs may slow progressive cartilage erosion and delay or even prevent the development of end-stage disease. α2-macroglobulin (α2M) is a member of the α2M family of proteins that circulate in the plasma at relatively high levels (2-4 mg/ml), and is also found in the joint fluid at similar concentrations (9). Since each subunit of the αM molecule has a region referred to as the ‘bait region’, which contains a cleavage site for a variety of proteinases (10), α2M is known as a ubiquitous proteinase inhibitor. An earlier study suggested that ADAMTS-1 activity may be inhibited by α2M and that inhibition of the aggrecanase may be mediated by proteolysis of the bait region within α2M (11). More recent studies have demonstrated that α2M is a novel substrate for ADAMTS-4, -5, -7 and -12, and may inhibit their activity in a concentration-dependent manner (6,10). In addition, studies have also demonstrated that α2M may be capable of inhibiting activated MMPs such as MMP-13 in body fluids (12,13). The studies suggested that the activated MMPs were entrapped by α2M and formed a complex with α2M in its presence, that the active site of the MMPs in the α2M/MMP complex was shielded and that the complex was also rapidly cleared by the body (13).

3. Loss of chondrogenic phenotype and Sox9

In addition to the degradation of the ECM, the loss of a chondrogenic phenotype is also a significant characteristic in OA. Chondrocytes are the only cell type found within articular cartilage and they are embedded in the tissue's highly specialized ECM. The interaction of chondrocytes with ECM makes a crucial contribution to the maintenance of a chondrogenic phenotype (14). Therefore, breakdown of ECM components may affect the homeostasis of chondrocytes and lead to the loss of a chondrogenic phenotype, which would further accelerate the pathological course of OA.

Sox9, a key chondrogenic transcription factor, played a significant role in the development and maintenance of the chondrogenic phenotype (15). One study demonstrated that Sox9 expression was relatively high in normal cartilage but that its transcript levels were substantially reduced in OA accompanied with the degradation of the ECM, this study also suggested that a reduction of Sox9 transcript levels in osteoarthritic chondrocytes may be responsible for the loss of phenotypic stability of osteoarthritic chondrocytes (16,17). This was further supported by the fact that transduction with
Sox9 enhanced re-expression of the chondrogenic phenotype in osteoarthritic chondrocytes (18). Thus, upregulation of Sox9 expression may promote the recovery of a chondrogenic phenotype.

4. Gene therapy of osteoarthritis

Genetic engineering offers a new treatment approach to the destructive processes in OA (19). Various efficacious genes have been found, and numerous genes have been induced into synovial cells (synoviocytes) and modified so that the destructive processes of OA can be delayed or prevented. A recent study has suggested that adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of OA (20). Gelse et al have also demonstrated that autologous periosteal cells stimulated ex vivo by bone morphogenetic protein 2 (BMP-2) gene transfer (adeno-associated virus and adenovirus vectors) can resurface large partial-thickness cartilage defects in a porcine model of OA (21). In addition, Zhang et al have shown that chitosan-DNA nanoparticles containing interleukin-1-receptor antagonist (IL-1Ra) are capable of reducing the severity of cartilage lesions by injecting directly into the knee joint cavities of OA rabbits (22). Therefore, gene transfers of defined genes encoding therapeutic proteins represent a promising way to efficiently treat OA.

5. Future directions

Due to the complex pathology of OA, gene transfer strategies based on co-expression of α2M and Sox9 genes will become of major interest for interfering with key process of the disease, and this will also be a highly specific targeting of OA-relevant mechanisms. At present, there are primarily two types of gene transfer system: viral and non-viral vectors. Although viral vectors acquired some benefits, non-viral vector delivery systems for gene therapy have been increasingly proposed as safer alternatives to viral vectors and they provide nontoxicity, low immunogenicity, stability, high DNA binding efficiency and easy manufacture. As a type of non-viral gene delivery system, chitosan has a host of other advantages: i) protecting DNA from nuclease degradation; ii) enhancing the transport of DNA across the cell membrane through interaction with specific membrane receptors; iii) releasing-gene in a controlled manner. In addition, due to the analogous structure in chitosan with glycosaminoglycans – one of the components of cartilage-specific ECM – chitosan has also been used in the treatment of certain joint diseases. Therefore, we propose that intra-articular injection of chitosan/plasmid DNA (containing α2M and Sox9 genes cloned into a plasmid as a whole body) will offer potential as a novel means to ameliorate OA.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 30801164) and the Innovation Program of Shanghai Municipal Education Commission (No. 09YZ107).

References